Epizyme scores FDA nod for rare cancer med Tazverik, but prices it for a future indication: analyst

24th January 2020 Uncategorised 0

Patients with epithelioid sarcoma previously had no targeted treatment options, but that’ll change with Epizyme’s approval for Tazverik. The FDA signed off on the drug Thursday, and the company plans a launch within 10 business days. Epizyme priced its rare cancer drug at $15,500 per month.

More: Epizyme scores FDA nod for rare cancer med Tazverik, but prices it for a future indication: analyst
Source: fierce